Structure of monoclonal antibodies

Biobetters: Protein Engineering to Approach the Curative

Volumn , Issue , 2015, Pages 81-89

  Moorthy, Balakrishnan S ^a   Xie, Bo ^a   Moussa, Ehab M ^a   Iyer, Lavanya K ^a   Chandrasekhar, Saradha ^a   Panchal, Jainik P ^a   Topp, Elizabeth M ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENGINEERING; INDUSTRIAL ENGINEERING;

MONOCLONAL ANTIBODIES;

EID: 84958646478     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-2543-8_6     Document Type: Chapter

References (33)

1. Alzari PM, Lascombe MB, Poljak RJ (1988) Three-dimensional structure of antibodies. Annu Rev Immunol 6:555-580.
2. Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, Mckelvey T, Li Y, Drummond J, Prueksaritanont T, Vlasak J (2009) Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 46:1878-1882.
3. Burton DR (1985) Immunoglobulin G: functional sites. Mol Immunol 22:161-206.
4. Burton DR, Woof JM (1992) Human antibody effector function. Adv Immunol 51:1-84.
5. Coloma MJ, Trinh RK, Martinez AR, Morrison SL (1999) Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1→6) dextran antibody. J Immunol 162:2162-2170.
6. Davies DR, Metzger H (1983) Structural basis of antibody function. Annu Rev Immunol 1:87-117.
7. Harris LJ, Larson SB, Hasel KW, Mcpherson A (1997) Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36:1581-1597.
8. Harris LJ, Skaletsky E, Mcpherson A (1998) Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 275:861-872.
9. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM (2005) In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 77:1432-1439.
10. Kato M, Mochizuki K, Hashizume S, Tachibana H, Shirahata S, Murakami H (1993) Activity enhancement of a lung cancer-associated human monoclonal antibody HB4C5 by N-deglycosylation. Hum Antibodies Hybridomas 4:9-14.
11. Khurana S, Raghunathan V, Salunke DM (1997) The variable domain glycosylation in a monoclonal antibody specific to GnRh modulates antigen binding. Biochem Biophys Res Commun 234:465-469.
12. Liu H, May K (2012) Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. mAbs 4:17-23.
13. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL Jr (2008) Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47:5088-5100.
14. Liu YD, Van Enk JZ, Flynn GC (2009) Human antibody Fc deamidation in vivo. Biologicals 37:313-322.
15. Mimura Y, Ashton PR, Takahashi N, Harvey DJ, Jefferis R (2007) Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J Immunol Methods 326:116-126.
16. Nose M, Wigzell H (1983) Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci U S A 80:6632-6636.
17. Padlan EA, Segal DM, Spande TF, Davies DR, Rudikoff S, Potter M (1973) Structure at 4.5 A resolution of a phosphorylcholine-binding fab. Nat New Biol 245:165-167.
18. Pan H, Chen K, Chu L, Kinderman F, Apostol I, Huang G (2009) Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci 18:424-433.
19. Pound JD, Lund J, Jefferis R (1993) Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. Mol Immunol 30:233-241.
20. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276:16469-16477.
21. Redpath S, Michaelsen TE, Sandlie I, Clark MR (1998) The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Hum Immunol 59:720-727.
22. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA (2001) Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293:1155-1159.
23. Satoh M, Iida S, Shitara K (2006) Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6:1161-1173.
24. Scallon BJ, Tam SH, Mccarthy SG, Cai AN, Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524-1534.
25. Segal DM, Padlan EA, Cohen GH, Rudikoff S, Potter M, Davies DR (1974) The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A 71:4298-4302.
26. Smith MA, Easton M, Everett P, Lewis G, Payne M, Riveros-Moreno V, Allen G (1996) Specific cleavage of immunoglobulin G by copper ions. Int J Pept Protein Res 48:48-55.
27. Sondermann P, Huber R, Oosthuizen V, Jacob U (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406:267-273.
28. Tachibana H, Seki K, Murakami H (1993) Identification of hybrid-type carbohydrate chains on the light chain of human monoclonal antibody specific to lung adenocarcinoma. Biochim Biophys Acta 1182:257-263.
29. Terry WD, Matthews BW, Davies DR (1968) Crystallographic studies of a human immunoglobulin. Nature 220:239-241.
30. Voynov V, Chennamsetty N, Kayser V, Helk B, Forrer K, Zhang H, Fritsch C, Heine H, Trout BL (2009) Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation. PLoS One 4:E8425.
31. Wallick SC, Kabat EA, Morrison SL (1988) Glycosylation of a VH residue of a monoclonal antibody against alpha (1-6) dextran increases its affinity for antigen. J Exp Med 168:1099-1109.
32. Wang X, Kumar S, Singh SK (2011) Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations. Pharm Res 28:3128-3144.
33. Wei Z, Feng J, Lin HY, Mullapudi S, Bishop E, Tous GI, Casas-Finet J, Hakki F, Strouse R, Schenerman MA (2007) Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal Chem 79:2797-2805.